JP2024523838A - Ox40及び/又はpd-l1に結合する抗体及び二重特異性結合タンパク質 - Google Patents

Ox40及び/又はpd-l1に結合する抗体及び二重特異性結合タンパク質 Download PDF

Info

Publication number
JP2024523838A
JP2024523838A JP2023575788A JP2023575788A JP2024523838A JP 2024523838 A JP2024523838 A JP 2024523838A JP 2023575788 A JP2023575788 A JP 2023575788A JP 2023575788 A JP2023575788 A JP 2023575788A JP 2024523838 A JP2024523838 A JP 2024523838A
Authority
JP
Japan
Prior art keywords
sequence
cdr
seq
antibody
antigen
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2023575788A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024523838A5 (cg-RX-API-DMAC7.html
Inventor
ゴン,シーヨン
リー,バオクン
リュー,ファン
ウー,チェンビン
ウー,シュアン
ザン,ルイ
Original Assignee
シャンハイ エピムアブ バイオセラピューティクス カンパニー リミテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by シャンハイ エピムアブ バイオセラピューティクス カンパニー リミテッド filed Critical シャンハイ エピムアブ バイオセラピューティクス カンパニー リミテッド
Publication of JP2024523838A publication Critical patent/JP2024523838A/ja
Publication of JP2024523838A5 publication Critical patent/JP2024523838A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2827—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/522—CH1 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/524—CH2 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/64—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising a combination of variable region and constant region components
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/72—Increased effector function due to an Fc-modification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/734—Complement-dependent cytotoxicity [CDC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/74—Inducing cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/75—Agonist effect on antigen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/70578—NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30 CD40 or CD95

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Food Science & Technology (AREA)
  • Microbiology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Cell Biology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
JP2023575788A 2021-06-09 2022-06-09 Ox40及び/又はpd-l1に結合する抗体及び二重特異性結合タンパク質 Pending JP2024523838A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CNPCT/CN2021/099228 2021-06-09
CN2021099228 2021-06-09
PCT/CN2022/097889 WO2022258015A1 (en) 2021-06-09 2022-06-09 Antibodies and bispecific binding proteins that bind ox40 and/or pd-l1

Publications (2)

Publication Number Publication Date
JP2024523838A true JP2024523838A (ja) 2024-07-02
JP2024523838A5 JP2024523838A5 (cg-RX-API-DMAC7.html) 2025-06-18

Family

ID=84425689

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023575788A Pending JP2024523838A (ja) 2021-06-09 2022-06-09 Ox40及び/又はpd-l1に結合する抗体及び二重特異性結合タンパク質

Country Status (10)

Country Link
US (1) US20250282881A1 (cg-RX-API-DMAC7.html)
EP (1) EP4352108A4 (cg-RX-API-DMAC7.html)
JP (1) JP2024523838A (cg-RX-API-DMAC7.html)
KR (1) KR20240019797A (cg-RX-API-DMAC7.html)
CN (1) CN117529503A (cg-RX-API-DMAC7.html)
AU (1) AU2022288037A1 (cg-RX-API-DMAC7.html)
CA (1) CA3221866A1 (cg-RX-API-DMAC7.html)
IL (1) IL308918A (cg-RX-API-DMAC7.html)
TW (1) TW202315893A (cg-RX-API-DMAC7.html)
WO (1) WO2022258015A1 (cg-RX-API-DMAC7.html)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN111201030B (zh) 2017-07-25 2024-11-01 真和制药有限公司 通过阻断tim-3和其配体的相互作用治疗癌症
KR20210124308A (ko) 2019-01-30 2021-10-14 트루바인딩 아이엔씨. 항-gal3 항체 및 이의 용도
MX2022014786A (es) 2020-05-26 2023-01-16 Truebinding Inc Metodos para tratar enfermedades inflamatorias mediante el bloqueo de galectina-3.

Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2017506215A (ja) * 2013-12-30 2017-03-02 エピムアブ バイオセラピューティクス インコーポレイテ タンデム型Fab免疫グロブリン及びその使用
JP2020514277A (ja) * 2016-12-23 2020-05-21 アールイーエムディー バイオセラピューティクス,インコーポレイテッドREMD Biotherapeutics,Inc プログラム死リガンド−1(pd−l1)に結合する抗体を使用する免疫
US20200231692A1 (en) * 2019-01-23 2020-07-23 Beijing Mabworks Biotech Co. Ltd Anti-ox40 antibodies and uses thereof
WO2020151761A1 (zh) * 2019-01-25 2020-07-30 信达生物制药(苏州)有限公司 结合pd-l1和ox40的双特异性抗体
EP3778648A1 (en) * 2018-03-27 2021-02-17 Innovent Biologics (Suzhou) Co., Ltd. Novel antibody molecule, and preparation method and use thereof
JP2021509258A (ja) * 2017-12-29 2021-03-25 エーピー バイオサイエンスィズ インコーポレイテッド 癌治療のために免疫チェックポイントを調節する単一特異性および二重特異性タンパク質
WO2021104434A1 (en) * 2019-11-27 2021-06-03 Shanghai Epimab Biotherapeutics Co., Ltd. TGFβ/PD-L1 BISPECIFIC BINDING PROTEINS

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN110325205B (zh) * 2016-12-22 2023-08-15 库尔生物制药有限公司 T细胞调节性多聚体多肽及其使用方法
SG11201912865VA (en) * 2017-06-25 2020-01-30 Systimmune Inc Multi-specific antibodies and methods of making and using thereof
CN111315405A (zh) * 2017-11-09 2020-06-19 免疫医疗有限责任公司 双特异性融合多肽及其使用方法
JP2021529557A (ja) * 2018-06-29 2021-11-04 ジェンサン バイオファーマ、 インコーポレイテッドGensun Biopharma, Inc. 抗腫瘍免疫チェックポイント調節因子アンタゴニスト
EP3880247A4 (en) * 2018-11-13 2022-10-26 JN Biosciences, LLC Bispecific antibodies for activation of immune cells
CN110003338B (zh) * 2019-04-16 2021-04-23 北京免疫方舟医药科技有限公司 抗ox40抗体及其应用

Patent Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2017506215A (ja) * 2013-12-30 2017-03-02 エピムアブ バイオセラピューティクス インコーポレイテ タンデム型Fab免疫グロブリン及びその使用
JP2020514277A (ja) * 2016-12-23 2020-05-21 アールイーエムディー バイオセラピューティクス,インコーポレイテッドREMD Biotherapeutics,Inc プログラム死リガンド−1(pd−l1)に結合する抗体を使用する免疫
JP2021509258A (ja) * 2017-12-29 2021-03-25 エーピー バイオサイエンスィズ インコーポレイテッド 癌治療のために免疫チェックポイントを調節する単一特異性および二重特異性タンパク質
EP3778648A1 (en) * 2018-03-27 2021-02-17 Innovent Biologics (Suzhou) Co., Ltd. Novel antibody molecule, and preparation method and use thereof
US20200231692A1 (en) * 2019-01-23 2020-07-23 Beijing Mabworks Biotech Co. Ltd Anti-ox40 antibodies and uses thereof
WO2020151761A1 (zh) * 2019-01-25 2020-07-30 信达生物制药(苏州)有限公司 结合pd-l1和ox40的双特异性抗体
WO2021104434A1 (en) * 2019-11-27 2021-06-03 Shanghai Epimab Biotherapeutics Co., Ltd. TGFβ/PD-L1 BISPECIFIC BINDING PROTEINS

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
BINGLIANG CHEN ET AL.: "The PD-L1 and OX40 bispecific antibody IBI327 induces immune activation and improves cancer immunoth", PROCEEDINGS OF THE ANNUAL MEETING OF THE AMERICAN ASSOCIATION FOR CANCER RESEARCH 2020, vol. vol.80(16 Suppl), JPN6026015106, 22 June 2020 (2020-06-22), pages 2268, ISSN: 0005847144 *
KUANG Z.: "A Novel Bispecific Antibody with PD-L1-assisted OX40 Activation for Cancer Treatment", MOL CANCER THER, vol. vol.19(12), JPN6026015105, December 2020 (2020-12-01), pages 2564 - 2574, ISSN: 0005847146 *
MICHAEL D. ET AL.: "A novel immunostimulatory OX40/PD-L1 bivalent bispecific antibody (MEDI1109) for the treatment of pa", PROCEEDINGS OF THE AMERICAN ASSOCIATION FOR CANCER RESEARCH ANNUAL MEETING 2018, vol. vol.78(13 Suppl), JPN6026015104, 14 April 2018 (2018-04-14), pages 2775, ISSN: 0005847145 *

Also Published As

Publication number Publication date
CN117529503A (zh) 2024-02-06
EP4352108A4 (en) 2026-01-07
IL308918A (en) 2024-01-01
KR20240019797A (ko) 2024-02-14
AU2022288037A9 (en) 2024-01-04
TW202315893A (zh) 2023-04-16
CA3221866A1 (en) 2022-12-15
WO2022258015A1 (en) 2022-12-15
EP4352108A1 (en) 2024-04-17
US20250282881A1 (en) 2025-09-11
AU2022288037A1 (en) 2023-12-14

Similar Documents

Publication Publication Date Title
JP7847630B2 (ja) Cd3およびbcmaに対する抗体およびそれらから作製した二重特異性結合タンパク質
TWI907489B (zh) 抗ror1抗體及相關雙特異性結合蛋白
TWI793129B (zh) 細胞毒性t淋巴球相關蛋白4 (ctla-4) 之新穎單株抗體
TW202302636A (zh) 靶向bcma、gprc5d及cd3之三特異性抗體
US12060425B2 (en) High affinity antibodies to PD-1 and LAG-3 and bispecific binding proteins made therefrom
CN108948194B (zh) 一种新的ctla-4单克隆抗体
WO2022258015A1 (en) Antibodies and bispecific binding proteins that bind ox40 and/or pd-l1
TWI772984B (zh) TGFβ/PD-L1雙特異性結合蛋白
TW202035448A (zh) 有效表現之egfr及pd-l1雙特異性結合蛋白
US20240317862A1 (en) Anti-b7-h3 monoclonal antibody and use thereof
TWI835166B (zh) 靶向pd-1和/或ox40的特異性結合蛋白及其應用
TWI833227B (zh) 靶向pd-l1和cd73的特異性結合蛋白及其應用
RU2852663C1 (ru) Антитела против cd3 и bcma и биспецифичные связывающие белки, полученные из них
RU2782381C2 (ru) Высокоаффинные анти-pd-1 и анти-lag-3 антитела и полученные из них биспецифические связывающие белки
TW202544031A (zh) 抗tigit/抗pd-l1雙特異性抗體及其用途
HK40067877A (en) Antibodies to cd3 and bcma, and bispecific binding proteins made therefrom

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20240229

RD01 Notification of change of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7426

Effective date: 20240229

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250609

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20250609

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20260423

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20260722